SPHDF Stock Chart & Stats
$22.28
$0.00(0.00%)
At close: 4:00 PM EST
$22.28
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$11.25 - $24.75
Previous CloseN/A
Volume890.00
Average Volume (3M)37.00
Market Cap
$277.07M
Enterprise Value$302.54M
Total Cash (Recent Filing)$22.44M
Total Debt (Recent Filing)$97.77M
Price to Earnings (P/E)―
Beta-0.45
Next Earnings
Sep 21, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.82
Shares Outstanding15,456,525
10 Day Avg. Volume40
30 Day Avg. Volume37
Financial Highlights & Ratios
PEG Ratio-1.37
Price to Book (P/B)-13.88
Price to Sales (P/S)2.12
P/FCF Ratio-4.71
Enterprise Value/Market Cap1.09
Enterprise Value/Revenue3.92
Enterprise Value/Gross Profit20.91
Enterprise Value/Ebitda-9.87
Forecast
1Y Price Target
$37.11Price Target Upside66.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.51
Revenue Forecast (FY)$119.09M
Bulls Say, Bears Say
Bulls Say
Approved Core Product (AGAMREE) In Rare DMD MarketHaving an approved therapy for Duchenne muscular dystrophy provides a durable commercial foothold in a specialty, high-barrier market. Approved status supports recurring product revenue, payer engagement and clinical credibility that underpin steady demand and strategic partnering opportunities.
Strong Revenue Rebound In 2025A sizable revenue rebound shows the company can grow sales materially when commercial execution and access align. Sustained top-line growth improves the probability of future positive cash generation, supports investment in launches and partnerships, and validates product uptake.
Monetization Via Partnerships And LicensingA business model that blends direct sales with licensing and royalties reduces capital intensity and enables geographic expansion without full commercial build-out. Partnership monetization offers durable non-dilutive cash inflection points and risk sharing on regulatory/commercial execution.
Bears Say
Negative Equity And Sharply Higher DebtNegative equity combined with a near-doubling of debt meaningfully weakens the capital structure and reduces financial flexibility. Elevated leverage increases refinancing and covenant risk, constraining the firm's ability to fund launches or absorb operational setbacks over the medium term.
Persistent Operating Cash BurnSustained negative operating and free cash flow near -35M per year implies ongoing reliance on external financing. Chronic cash burn limits runway, forces financing-driven dilution or debt, and restricts investments in commercialization and R&D that are needed to achieve durable profitability.
Volatile Profitability; Return To Deep LossesWide swings from prior profitable years to a ~49M net loss show an unstable earnings base, making future margin sustainability uncertain. This volatility complicates planning, weakens lender and partner confidence, and raises execution risk for converting revenue growth into lasting profits.
Santhera Pharmaceuticals Holding News
SPHDF FAQ
What was Santhera Pharmaceuticals Holding’s price range in the past 12 months?
Santhera Pharmaceuticals Holding lowest stock price was $11.25 and its highest was $24.75 in the past 12 months.
What is Santhera Pharmaceuticals Holding’s market cap?
Santhera Pharmaceuticals Holding’s market cap is $277.07M.
When is Santhera Pharmaceuticals Holding’s upcoming earnings report date?
Santhera Pharmaceuticals Holding’s upcoming earnings report date is Sep 21, 2026 which is in 67 days.
How were Santhera Pharmaceuticals Holding’s earnings last quarter?
Santhera Pharmaceuticals Holding released its earnings results on Apr 28, 2026. The company reported -$0.531 earnings per share for the quarter, the consensus estimate of -$0.531 by $0.
Is Santhera Pharmaceuticals Holding overvalued?
According to Wall Street analysts Santhera Pharmaceuticals Holding’s price is currently Undervalued.
Does Santhera Pharmaceuticals Holding pay dividends?
Santhera Pharmaceuticals Holding does not currently pay dividends.
What is Santhera Pharmaceuticals Holding’s EPS estimate?
Santhera Pharmaceuticals Holding’s EPS estimate is -0.11.
How many shares outstanding does Santhera Pharmaceuticals Holding have?
Santhera Pharmaceuticals Holding has 15,456,525 shares outstanding.
What happened to Santhera Pharmaceuticals Holding’s price movement after its last earnings report?
Santhera Pharmaceuticals Holding reported an EPS of -$0.531 in its last earnings report, expectations of -$0.531. Following the earnings report the stock price went up 1.751%.
Which hedge fund is a major shareholder of Santhera Pharmaceuticals Holding?
Currently, no hedge funds are holding shares in SPHDF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Santhera Pharmaceuticals Holding
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and sells medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the Europe, North America, and Asia. The company’s lead pipeline candidate includes Vamorolone, which is developed for the treatments of Duchenne muscular dystrophy. Its clinical stage pipeline also comprises Lonodelestat for the treatment of cystic fibrosis and other neutrophilic pulmonary diseases. Santhera Pharmaceuticals Holding AG was founded in 2004 and is based in Pratteln, Switzerland.
SPHDF Stock 12 Month Forecast
Average Price Target
$37.11
▲(66.55% Upside)
Technical Analysis
Molecular Partners AG
―
Basilea Pharmaceutica
―
Idorsia Ltd
―
Newron Pharmaceuticals SpA
―
Xlife Sciences Ltd.
―
Ownership Overview
―
Insiders
0.08% Mutual Funds
― Other Institutional Investors
99.47% Public Companies and
Individual Investors